ResearcherChina Pharmaceutical UniversityActive in the last 2 years

Xuanning Chu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0001-8042-4596; OpenAlex author ID A5111254932. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2024: 1 paper · 2025: 1 paper

Papers 2

HACD2 Promotes Pancreatic Cancer Progression by Enhancing PKM2 Dissociation From PRKN in a Dehydratase-Independent Manner. Co-author DOI 10.1002/advs.202407942 ↗
ROCK1 regulates glycolysis in pancreatic cancer via the c-MYC/PFKFB3 pathway. Co-author DOI 10.1016/j.bbagen.2024.130669 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Changlin Zhou · 1 shared paper, 2025 · strength 0.28
- Paper HACD2 Promotes Pancreatic Cancer Progression by Enhancing PKM2 Dissociation From PRKN in a Dehydratase-Independent Mann… DOI 10.1002/advs.202407942 ↗
Yu Zhou · 1 shared paper, 2025 · strength 0.28
- Paper HACD2 Promotes Pancreatic Cancer Progression by Enhancing PKM2 Dissociation From PRKN in a Dehydratase-Independent Mann… DOI 10.1002/advs.202407942 ↗
Shuyang Pang · 1 shared paper, 2024 · strength 0.26
- Paper ROCK1 regulates glycolysis in pancreatic cancer via the c-MYC/PFKFB3 pathway. DOI 10.1016/j.bbagen.2024.130669 ↗
Yiran Zhou · 1 shared paper, 2024 · strength 0.26
- Paper ROCK1 regulates glycolysis in pancreatic cancer via the c-MYC/PFKFB3 pathway. DOI 10.1016/j.bbagen.2024.130669 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.